State-of-the-Art Review: Managing Vulvovaginal Candidiasis - PubMed
4 hours ago
- #Recurrent infections
- #Antifungal therapies
- #Vulvovaginal candidiasis
- Vulvovaginal candidiasis is a prevalent infection affecting millions of women globally.
- Recurrent vulvovaginal candidiasis significantly impacts quality of life.
- Candida albicans is the primary cause, but non-albicans species are increasingly common.
- Risk factors include hormonal changes, diabetes, antibiotic use, immune dysfunction, and genetics.
- The vaginal microbiome plays a crucial role in preventing Candida overgrowth.
- Symptoms like itching, discharge, and soreness complicate diagnosis due to overlap with other conditions.
- Standard treatments involve topical or systemic antifungals, but recurrence and resistance are common issues.
- Emerging strategies include novel antifungals, immunomodulators, and vaccines.
- Future approaches should focus on modulating host and environmental factors to improve outcomes.